EQS-News  137  0 Kommentare Formycon hosts conference call on the results of the first quarter 2024 - Seite 2

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/Ranibizumab, Formycon already has a biosimilar on the market in Europe and the USA. Another five biosimilar candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines. Formycon AG is headquartered in Munich and is listed on the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY. Further information can be found at: https://www.formycon.com/

Lesen Sie auch

EZB-Zinssenkung am Donnerstag

Hat sich Christine Lagarde zu weit aus dem Fenster gelehnt?

04.06.24, 16:33

1 Kommentar

Geleakte E-Mails

Hat Elon Musk Nvidia angewiesen, KI-Chips für Tesla an andere Firmen umzuleiten?

04.06.24, 16:08

 

XRP News: Experte mit scharfer Warnung – 1 $ ist erst der Anfang

02.06.24, 06:13

Anzeige

Experten sehen Preisexplosion

Massive US-Verschuldung könnte Bitcoin auf 1 Million US-Dollar katapultieren

31.05.24, 15:59

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare providers. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

Diskutieren Sie über die enthaltenen Werte

Formycon

Aktie

Beiträge: 4.400